The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Percutaneous coronary intervention of saphenous vein grafts: where do we stand?

EuroIntervention 2018;14:142-143. DOI: 10.4244/EIJV14I2A22

1. Norfolk and Norwich University Hospital, Norwich, United Kingdom; 2. Keele Cardiovascular Research Group, Keele University, and University Hospital of North Staffordshire, Stoke-on-Trent, United Kingdom

Saphenous vein grafts (SVG) are known to be more susceptible to accelerated atherosclerosis than native coronary arteries1. Accelerated atherosclerosis in SVG develops from resident foam cells, which then undergo apoptosis to form necrotic cores1. The attrition rate of SVG is around 2% per year for the first seven years, rising to 5% per year thereafter. Less than half of all SVG remain patent by 10 years. SVG intervention is usually undertaken in a group of patients carrying a higher risk profile, accounting for around 10% of all percutaneous coronary intervention (PCI) cases1.

RRISC (Reduction of Restenosis In Saphenous Vein Grafts With Cypher ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
FOURIER to ODYSSEY: the end of the journey for lipid-lowering therapy trials? Lessons from recent clinical trials with anti-PCSK9 antibodies